<DOC>
	<DOCNO>NCT02915666</DOCNO>
	<brief_summary>This study do find combination dabrafenib , trametinib digoxin lessen side effect may experience measure response duration response combination drug .</brief_summary>
	<brief_title>A Clinical Trial Patients With Melanoma</brief_title>
	<detailed_description>Melanoma cancer melanocyte -- melanin pigment produce cell , cancer originates skin , uvea , acral tissue mucosal tissue . Melanoma incidence mortality increase U.S. 80,000 cases/year 9,000 deaths/year . Advanced melanoma occur either treatment localized melanoma de novo associate chemo-resistance median survival 9 month . The study prospective , single-arm , one-site therapeutic trial combination Dabrafenib + Trametinib + Digoxin advance V600 mutant melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>1 . Histologic diagnosis unresectable metastatic BRAF V600 mutant melanoma . 2 . Age &gt; 18 year . 3 . Naïve number prior systemic therapeutic regimen unresectable stage III stage IV melanoma , except prior BRAF MEK inhibitor agent . This include chemotherapy , immunotherapy , biochemotherapy , investigational treatment . Patients may also receive therapy adjuvant setting . 4 . Performance status ECOG 02 . 5 . Adequate organ function define : A. total bilirubin 3 x institutional upper limit normal B. AST ( SGOT ) /ALT ( SPGT ) ≤ 5 X institutional upper limit normal C. creatinine 3 mg/dL D. cardiac ejection fraction &gt; 50 % E. QTcF ≤ 480msec F.PT/INR/aPTT ≤ 1.5 x institutional upper limit normal 6 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 4 month follow completion therapy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . A female childbearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : undergone hysterectomy bilateral oophorectomy ; naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 7 . All sit disease must evaluate within 4 week prior begin therapy . Patients must measurable disease define RECIST v1.1 ( see Section 6 ) . 8 . Ability understand willingness sign write informed consent . Exclusion Criteria 1 . Subjects chemotherapy radiotherapy systemic therapy melanoma within 3 week prior enter study recover adverse event due agent administer 3 week earlier . No concomitant therapy allow include IL2 , interferon , ipilimumab , antiPD1 antiPDL1 antibody , cytotoxic chemotherapy , immunosuppressive agent , investigational therapy . 2 . Active infection hepatitis B C HIV . 3 . Subjects active CNS disease exclude . Patient brain metastases previously treat surgery radiation therapy confirm SD &gt; 2 week allow . 4 . Patients exclude history malignancy patient diseasefree less 2 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( &gt; class II base NYHA ) , unstable angina pectoris , clinically significant uncontrolled cardiac arrhythmia , uncontrolled thyroid disease , psychiatric illness/social situation would limit compliance study requirement . Acute coronary syndrome within 24 week . Note atrial fibrillation control &gt; 30 day exclusion . 6 . History predisposition retinal vein occlusion central serous retinopathy . 7 . Prior BRAF MEK inhibitor therapy . 8 . WolffParkinson White syndrome presence intracardiac defibrillator ( see Section 7.2.1 ) . 9 . Known cardiac metastasis . 10 . History interstitial lung disease unresolved pneumonitis . 11 . Immediate delay hypersensitivity digoxin . 12 . Patients require concomitant medication list section 4.3 able switch reasonable alternative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Melanoma , skin</keyword>
</DOC>